Stay updated with breaking news from Andy Plump. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Takeda Pharmaceutical Company Limited (NYSE:TAK) Q2 2023 Earnings Call Transcript October 27, 2023 Christopher O’Reilly: Thank you very much for joining us out of your busy schedule today for the earnings call for Second Quarter Fiscal 2023 with Takeda Pharmaceutical Company Limited. I am going to be the moderator today O’Reilly, the Head of IR. […]
Christopher O'Reilly: Thank you very much for joining us out of your busy schedule today for the earnings call for Second Quarter Fiscal 2023 with Takeda Pharmaceutical Company Limited.
In a symbolic act, the foundation stone was laid for Takeda's
− Topline Results for TAK-279 Show that a Significantly Greater Proportion of Psoriatic Arthritis Patients Achieved at Least an ACR20 Response Compared to Placebo at Week 121 − Based on the...
Takeda TSE4502NYSETAK today announced positive topline results from its randomized doubleblind placebocontrolled multipledose Phase 2b trial evaluating TAK279 an investigational oral allosteric tyrosine kinase 2 TYK2 inhibitor with next generation selectivity in people with active psoriatic arthritis.